Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2009

01-04-2009 | Breast Oncology

Sentinel Node Biopsy in Patients with Previous Breast Aesthetic Surgery

Authors: Julia Rodriguez Fernandez, MD, Stefano Martella, MD, Giuseppe Trifirò, MD, Mujgan Caliskan, MD, Camelia Chifu, MD, Fabricio Brenelli, MD, Edoardo Botteri, MSc, Fabio Rossetto, Nicole Rotmensz, MSc, Mario Rietjens, MD, Paolo Veronesi, MD

Published in: Annals of Surgical Oncology | Issue 4/2009

Login to get access

Abstract

Background

Sentinel lymph node biopsy (SLNB) is the standard method for axillary staging of early breast cancer. Recent studies have focused on questioning the initial contraindication to the technique. There has been insufficient data to recommend SLNB in patients with previous aesthetic breast surgery.

Materials and Methods

Between April 2001 and June 2007, 70 patients with previous breast aesthetic surgery underwent SLNB. Fifty had a previous breast augmentation and 20 had breast reduction mammoplasty. All patients underwent lymphoscintigraphy with 99Tc according to our standard technique and sentinel node was identified in all cases.

Results

Mean age at cosmetic surgery was 38 years. Mean number of years from aesthetic surgery to the development of the tumour was 10 years. Forty-nine patients underwent conservative breast surgery and 21 patients underwent mastectomy. The sentinel node identification rate was 100%. SLN was positive in 23 patients (32%); there were 18 cases with macrometastasis and 7 cases with micrometastasis. After median follow-up of 19 months, no axillary recurrences have been observed. We observed two ipsilateral local recurrences, one contralateral tumour and one patient developed lung metastasis.

Conclusions

Past history of breast augmentation or reduction is not a contraindication to SLNB technique.
Literature
1.
Krag D, Weaver D, Ashikana T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med. 1998;339:941–6.PubMedCrossRef
2.
Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006;7:983–90.PubMedCrossRef
3.
Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, et al. Sentinel node biopsy can avoid axillary dissection in breast cancer patients with clinically negative lymph-nodes. Lancet. 1997;349:1864–7.PubMedCrossRef
4.
Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703–20. Epub 2005 Sep 12.PubMedCrossRef
5.
Luini A, Galimberti V, Gatti G, Arnone P, Vento AR, Trifiro G, et al. The sentinel node biopsy after previous breast surgery: preliminary results on 543 patients treated at the European Institute of Oncology. Breast Cancer Res Treat. 2005;89(2):159–63.PubMedCrossRef
6.
Heuts EM, van der Ent FW, Kengen RA, van der Pol HA, Hulsewe KW, Hoofwijk AG. Results of sentinel node biopsy not affected by previous excisional biopsy. Eur J Surg Oncol. 2006;32(3):278–81. Epub 2005 Oct 24.PubMedCrossRef
7.
Haigh PI, Hansen NM, Qi K, Giuliano AE. Biopsy method and excision volume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer. Ann Surg Oncol. 2000;7:21–7.PubMedCrossRef
8.
Wong SL, Edwards MJ, Chao C, Tuttle TM, Noyes RD, Carlson DJ, et al. The effect of prior breast biopsy method and concurrent definitive breast procedure on success and accuracy of sentinel lymph node biopsy. Ann Surg Oncol. 2002;9(3):272–7.PubMedCrossRef
9.
Cody HS III. Sentinel lymph node biopsy for breast cancer: indications, contraindications, and new directions. J Surg Oncol. 2007;95(6):440–2.PubMedCrossRef
10.
Intra M, Rotmensz N, Mattar D, Gentilini OD, Vento A, Veronesi P, et al. Unnecessary axillary node dissections in the sentinel lymph node era. Eur J Cancer. 2007;43(18):2664–8. Epub 2007 Oct 10.PubMedCrossRef
11.
Paganelli G, Galimberti V, Trifirò G, Travaini L, De Cicco C, Mazzarol G, et al. Internal mammary node lymphoscintigraphy and biopsy in breast cancer. Q J Nucl Med. 2002;46:138–44.PubMed
12.
Ries LAG, Eisner MP, Kosary CL. SEER cancer statistics review 1975–2002. Bethesda, MD: National Cancer Institute; 2005.
13.
Taback B, Nguyen P, Hansen sentinel lymph node biopsy for local recurrence of breast cancer after breast-conserving therapy. Ann Surg Oncol. 2006;13(8):1099–104. Epub 2006 Jun 21.PubMedCrossRef
14.
Intra M, Trifirò G, Galimberti V. Second axillary sentinel node biopsy for ipsilateral breast tumour recurrence. Br J Surg. 2007;94(10):1216–9.PubMedCrossRef
15.
Munhoz AM, Aldrighi C, Buschpiegel C, Ono C, Montag E, Fells K, et al. The feasibility of sentinel lymph node detection in patients with previous transaxillary implant breast augmentation: preliminary results. Aesth Plast Surg. 2005;29:163–8.CrossRef
16.
Prado A, Andrades P, Leniz P. Implications of Transaxillary Breast Augmentation: Lifetime Probability of Breast Cancer Development and Sentinel Node Mapping Interference. Aesth Plast Surg. 2007;31:317–9.CrossRef
17.
Mottura AA, Del Castillo R. Transaxillary breast augmentation: two breast cancer patients with successful sentinel lymph node diagnosis. Aesth Plast Surg. 2007;31:544–9.CrossRef
Metadata
Title
Sentinel Node Biopsy in Patients with Previous Breast Aesthetic Surgery
Authors
Julia Rodriguez Fernandez, MD
Stefano Martella, MD
Giuseppe Trifirò, MD
Mujgan Caliskan, MD
Camelia Chifu, MD
Fabricio Brenelli, MD
Edoardo Botteri, MSc
Fabio Rossetto
Nicole Rotmensz, MSc
Mario Rietjens, MD
Paolo Veronesi, MD
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 4/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0349-0

Other articles of this Issue 4/2009

Annals of Surgical Oncology 4/2009 Go to the issue

Breast Oncology

Neoadjuvant Chemotherapy for Breast Cancer: Does Pretreatment Axillary Nodal Staging Improve Decision Making?

Bone and Soft Tissue Sarcomas

Nanoneoadjuvant Therapy of Gastrointestinal Stromal Tumor (GIST)

Hepatobiliary and Pancreatic Tumors

Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma

Gastrointestinal Oncology

Perioperative Chemotherapy for Gastric Cancer: How Should We Measure the Efficacy?

Hepatobiliary and Pancreatic Tumors

Does Portal-Superior Mesenteric Vein Invasion Still Indicate Irresectability for Pancreatic Carcinoma?

Gastrointestinal Oncology

APC, MYH, and the Correlation Genotype-Phenotype in Colorectal Polyposis